You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Financial news, mergers and acquisitions, partnerships, and alliances.
The investment bank gave a price target of $3.33 per share for Aspira, which focuses on women's health, and $11.97 for dermatology firm DermTech.
Oxsed, a University of Oxford spinout, will continue to focus on prioritizing test access for low- and middle-income countries following the acquisition.
The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.
Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.
